摘要
[目的]探讨乳腺癌患者血清UBE2C的表达及临床意义。[方法]收集保定市第一中心医院乳腺癌患者42例、乳腺良性结节18例,同期选择体检健康人20例为对照组,运用酶联免疫吸附法(ELISA)测定并比较术前乳腺癌患者、乳腺良性结节、正常健康人血清UBE2C蛋白含量。分析乳腺癌患者血清UBE2C表达水平与年龄、肿瘤直径、淋巴结转移、ER、PR、病理类型、组织学分级、病理分期(TNM)、临床分期、分子类型、Her-2等临床病理特征相关性。ELISA法测定乳腺癌患者术后7d血清UBE2C蛋白含量,并与术前水平比较。[结果]乳腺癌患者血清UBE2C表达的平均浓度(841.64±134.03pg/ml)高于乳腺良性结节患者(286.49±32.74pg/ml)和健康对照组(268.11±51.02pg/ml)。乳腺癌患者血清中UBE2C表达水平与年龄、肿瘤直径、淋巴结转移、ER、PR无显著性相关(P>0.05),但与病理类型、组织学分级、病理分期(TNM)、临床分期、分子类型、Her-2等显著性相关(P<0.05)。[结论]乳腺癌患者血清UBE2C蛋白水平升高,与乳腺癌的病程进展联系密切,有望成为乳腺癌患者不良预后的指标之一。
[Objective]To investigate the expression and clinical significance of serum UBE2C in breast cancer patients.[Methods]Forty two patients with breast cancer and 18 patients with benign breast nodules were enrolled from the Baoding First Central Hospital,and 20 healthy subjects served as the control group.The levels of serum UBE2C in breast cancer patients before and after operation were measured by enzyme-linked immunosorbent assay(ELISA),the UBE2C levels in patients with benign breast nodules and normal healthy subjects were also measured.The correlation of serum UBE2C levels with age,tumor size,lymph node metastasis,ER,PR,pathological type,histological grade,pathological staging(TNM),clinical stage,the types of molecules,Her-2 and other clinicopathological features was analyzed.[Results]The serum UBE2C level in breast cancer patients before operation(841.64±134.03 pg/ml)was significantly higher than that in benign breast nodules(286.49±32.74 pg/ml,P<0.05)and healthy controls(268.11±51.02 pg/ml,P<0.05),and it was not significantly decreased after surgery(829.58±149.24 pg/ml,P>0.05).Serum UBE2C levels in breast cancer were not correlated with age,tumor size,lymph node metastasis,ER and PR,but significantly correlated with pathological type,histological grade,pathological stage(TNM),clinical stage,molecular type and Her-2.[Conclusion]Serum UBE2C level is elevated in breast cancer patients,and it is related closely to progression of breast cancer.
作者
魏震
苌琬梅
王前
张惠卿
WEI Zhen;CHANG Wan-mei;WANG Qian;ZHANG Hui-qing(Chengde Medical College,Chengde067000,China;Chengde Medical College,Baoding First Central Hospital,Baoding071000,China)
出处
《肿瘤学杂志》
CAS
2019年第5期423-426,共4页
Journal of Chinese Oncology
基金
河北省卫生计委科研基金(20171069)
